NCT01129206: Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy |
|
|
| Completed | 2 | 6 | US | pralatrexate, FOLOTYN, PDX, docetaxel, RP 56976, Taxotere, TXT, fludeoxyglucose F 18, 18FDG, FDG, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, fluorodeoxyglucose F 18, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed | Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, Spectrum Pharmaceuticals, Inc | Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer | 09/12 | | | |
NCT01178944: Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer |
|
|
| Completed | 2 | 35 | US | Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Pralatrexate, 10-propargyl-10-deazaaminopterin, Folotyn, PDX | Roswell Park Cancer Institute, National Cancer Institute (NCI), National Comprehensive Cancer Network | Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Gastric Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Carcinoma, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Carcinoma, Stage IIIC Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Undifferentiated Gastric Carcinoma | 01/15 | 11/15 | | |
